The EBF1-PDGFRB T681I mutation is highly resistant to imatinib and dasatinib in vitro and detectable in clinical samples prior to treatment
- Resource Type
- Source
- Haematologica. 106:2242-2245
- Subject
business.industry Imatinib PDGFRB Hematology In vitro Dasatinib 03 medical and health sciences 0302 clinical medicine 030220 oncology & carcinogenesis Mutation (genetic algorithm) Cancer research Medicine business 030215 immunology medicine.drug - Language
- ISSN
- 1592-8721
0390-6078